Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Medtronic, Genzyme and Depuy Dominate the Global Orthobiologics Market: companiesandmarkets.com

Abstract:
- Global orthobiologics market to be worth $9.6 billion in 2016, growing at a CAGR of 12%
- 350 million people have arthritis globally, with over half of those under the age of 65
- Medtronic, Genzyme and Depuy dominate the global orthobiologics market

Medtronic, Genzyme and Depuy Dominate the Global Orthobiologics Market: companiesandmarkets.com

London, UK | Posted on August 31st, 2011

The global market for orthobiologics was valued at $4.3 billion in 2009, and is set to reach $9.6 billion in 2016, representing a CAGR of 12%. Bone graft substitutes will remain the largest segment in the market, with a value of $5.3 billion by 2016. Growth in the orthobiologics market is being driven by the increasing incidence of arthritis, an increasingly elderly population, and higher obesity rates. Globally, about 350 million people have arthritis, and more than half of arthritis sufferers are under 65 years of age.

Orthobiologics Market to 2016 - Alternatives to Surgery and Superior Outcomes are Driving Wider Adoption of Orthobiologics

http://www.companiesandmarkets.com/Market-Report/orthobiologics-market-to-2016-alternatives-to-surgery-and-superior-outcomes-are-driving-wider-adoption-of-orthobiologics-686105.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The US orthobiologics market was valued at $2.3 billion in 2009, and is expected to reach $6 billion in 2016, representing a CAGR of 15% for the period. The US remains the largest orthobiologics market in the world, accounting for more than 50% of the global orthobiologics market in 2009. The orthobiologics market in the US is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents.

The global orthobiologics market was dominated by Medtronic, Genzyme and Depuy, which together accounted for nearly 40% of the market in 2009. Medtronic is market leader, with a 19% share in 2009. Medtronic's InFUSE bone graft was its major revenue generator in the orthobiologics market during the first quarter of 2009. Genzyme was the second largest company, with a market share of 11%, followed by Depuy with 10%.

The orthobiologics product pipeline is strong, with about 134 products making their way to market. These products are aimed at reducing rejection rates, stimulating the growth of bone and improving patient outcomes. The advantages offered and the simplicity in use of many of these products is expected to increase their uptake. Nanotechnology will be the key driver of growth in the orthobiologics market in the future.

####

For more information, please click here

Contacts:
Companies & Markets
Paul Chapman
Press Office

London (UK): +44 (0) 203 086 8600

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

INVECAS to Enable ASIC Designs for Tomorrows Intelligent Systems on GLOBALFOUNDRIES' FDX Technology: INVECAS to Collaborate with GLOBALFOUNDRIES to Provide IP and End-to-End ASIC Design Services on 22FDX and 12FDX Technologies September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Innovation in Nanotechnology is Focus of Symposium: Annual event brings international experts to Northwestern Oct. 6 September 29th, 2016

Possible Futures

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Nanosensors could help determine tumors ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Crystalline Fault Lines Provide Pathway for Solar Cell Current: New tomographic AFM imaging technique reveals that microstructural defects, generally thought to be detrimental, actually improve conductivity in cadmium telluride solar cells September 26th, 2016

Nanomedicine

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Nanosensors could help determine tumors ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Announcements

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

INVECAS to Enable ASIC Designs for Tomorrows Intelligent Systems on GLOBALFOUNDRIES' FDX Technology: INVECAS to Collaborate with GLOBALFOUNDRIES to Provide IP and End-to-End ASIC Design Services on 22FDX and 12FDX Technologies September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Innovation in Nanotechnology is Focus of Symposium: Annual event brings international experts to Northwestern Oct. 6 September 29th, 2016

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Nanosensors could help determine tumors ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Crystalline Fault Lines Provide Pathway for Solar Cell Current: New tomographic AFM imaging technique reveals that microstructural defects, generally thought to be detrimental, actually improve conductivity in cadmium telluride solar cells September 26th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic